SCHEMBL7200949

SCHEMBL7200949

Cc1cccc(OC2CCN(S(=O)(=O)C3CCNCC3(O)C(=O)NO)CC2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 3/20 0.45
MMP1 P03956 2/20 0.45
EPHX2 P34913 1/20 0.42
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
ADAM17 P78536 1/20 0.39
RAB9A P51151 3/20 0.39
POLB P06746 2/20 0.38
NPC1 O15118 1/20 0.38
HTR2C P28335 1/20 0.37
HRH3 Q9Y5N1 1/20 0.37
SLC6A2 P23975 1/20 0.37
SLC6A4 P31645 1/20 0.37
SLC6A3 Q01959 1/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HRH1 P35367 1/20 0.37
CCR3 P51677 1/20 0.37
FPR2 P25090 1/20 0.36
PROKR1 Q8TCW9 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7202693 0.91 FPR2 (0.44) MMP13MMP1EPHX2KMT2AADAM17
SCHEMBL7206963 0.89 HTR2C (0.49) MMP13MMP1EPHX2RAB9AHTR2C
SCHEMBL7202653 0.89 MLNR (0.45) MMP13KMT2AMEN1RAB9AHTR2C
SCHEMBL7200991 0.89 MMP13 (0.43) MMP13MMP1EPHX2KMT2AMEN1
SCHEMBL7199648 0.88 HTR2C (0.44) MMP13EPHX2ADAM17HTR2CHRH1
SCHEMBL7202351 0.85 ADAM17 (0.45) MMP13ADAM17FPR2PROKR1
SCHEMBL7200927 0.85 MMP13 (0.46) MMP13MMP1ADAM17POLB
SCHEMBL7201546 0.85 SMN1; SMN2 (0.48) MMP13MMP1EPHX2FPR2PROKR1
SCHEMBL7202576 0.84 MMP13 (0.64) MMP13MMP1POLB
SCHEMBL7202601 0.84 MMP2 (0.49) MMP13MMP1ADAM17HTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6608104-B2 Antiarthritic agents; anticancer agents PFIZER INC 2003-08-19 US disclosed
US-20020019534-A1 Gem substituted hydroxamic acids PFIZER INC. 2002-02-14 US disclosed
EP-1138680-A1 Gem substituted sulfonyl hydroxamic acids as MMP inhibitors Pfizer Products Inc. (US) 2001-10-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019534-A1 Gem substituted hydroxamic acids MMP14, TOP2A, ADAMTS1 MMP13 4/4885MMP1 8/4885EPHX2 368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.